Alex is a fast caffeine metabolizer.
Alex carries the AA genotype at CYP1A2 rs762551 — the fast-metabolizer allele. Caffeine clears his bloodstream roughly twice as fast as the average drinker, so a late espresso is unlikely to wreck his sleep, and his cardiovascular risk from moderate coffee intake is on the lower end of the published range. This is one of three notable findings in his DeepDNA report.
Three variants drove this report.
DeepDNA scans 600,000+ SNPs from your raw file. The variants below are the ones with the clearest published evidence for Alex's lifestyle and health.
Caffeine: the fast lane.
The CYP1A2 gene encodes the liver enzyme that breaks down about 95% of dietary caffeine. The rs762551 variant flips a single base in the gene's promoter — the region that decides how often the gene is read. Alex's AA genotype turns the dial up: more enzyme, faster clearance.
"For Alex, a 2pm espresso has a half-life of roughly 2.5 hours — about 60% of the typical 4-hour clearance. Translation: caffeine is unlikely to disrupt his sleep at moderate doses."
The same variant has been studied for its link to coffee and heart attack risk. In carriers of the AA (fast) genotype, observational studies have not found the elevated risk seen in slow metabolizers. Alex's report flags this as a low-priority cardiovascular item.
A second finding — heterozygous MTHFR C677T — shows up in about 30% of Europeans and modestly reduces folate processing. Practical impact: keep leafy greens and legumes in regular rotation.
Three concrete things to do.
- Coffee is fine, even late. Up to 400 mg/day (≈4 cups) is the published safe range; Alex's genotype puts him on the tolerant end.
- Folate over folic acid. With the MTHFR C677T variant, methylfolate is the form his body uses most efficiently. Food sources beat supplements where possible.
- Watch caffeine + anxiety days. The ADORA2A CT genotype means caffeine can amplify jitter on already-stressful days. Decaf before public speaking is a small, evidence-backed hack.
Sources cited in Alex's full report: PharmGKB (CYP1A2 PA164745064), ClinVar (rs1801133), Cornelis et al. JAMA 2006, Childs et al. AJCN 2008.